Bottleneck limitations for microRNA-based therapeutics from bench to the bedside

Pharmazie

Volumn 70, Issue 3, 2015, Pages 147-154

  Chen, Yan ^a,b   Zhao, Hongliang ^a   Tan, Zhijun ^c   Zhang, Cuiping ^b   Fu, Xiaobing ^a,b  

^a CHINESE PLA GENERAL HOSPITAL   (China)

^b CHINESE PLA GENERAL HOSPITAL   (China)

^c TIANJIN MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

MICRORNA; NANOPARTICLE;

BASIC RESEARCH; BIOLOGICAL FUNCTIONS; CLINICAL PRACTICE; DRUG DELIVERY SYSTEM; HUMAN; IMMUNOGENICITY; INNATE IMMUNITY; REPRODUCIBILITY; REVIEW; ANIMAL; DRUG EFFECTS; GENE REPRESSION; GENE VECTOR; GENETICS; MEDICAL RESEARCH; NEOPLASMS;

ANIMALS; BIOMEDICAL RESEARCH; GENETIC VECTORS; HUMANS; MICRORNAS; NEOPLASMS; SUPPRESSION, GENETIC;

EID: 84930238958     PISSN: 00317144     EISSN: None     Source Type: Journal    
DOI: 10.1691/ph.2015.4774     Document Type: Review

References (93)

1. Ali AS, Ali S, Ahmad A, Bao B, Philip PA, Sarkar FH (2011) Expression of microRNAs: potential molecular link between obesity, diabetes and cancer. Obes Rev 12: 1050-1062.
2. Allard E, Passirani C, Benoit JP (2009) Convection-enhanced delivery of nanocarriers for the treatment of brain tumors. Biomaterials 30: 2302-2318.
3. Astuti D, Morris MR, Cooper WN, Staals RH,Wake NC, Fews GA, Gill H, Gentle D, Shuib S, Ricketts CJ, Cole T, van Essen AJ, van Lingen RA, Neri G, Opitz JM, Rump P, Stolte-Dijkstra I, Muller F, Pruijn GJ, Latif F, Maher ER (2012) Germline mutations in DIS3L2 cause the Perlman syndrome of overgrowth and Wilms tumor susceptibility. Nat Genet 44: 277-284.
4. Bader AG, Brown D, Stoudemire J, Lammers P (2011) Developing therapeutic microRNAs for cancer. Gene Ther 18: 1121-1126.
5. Baek D, Villen J, Shin C, Camargo FD, Gygi SP, Bartel DP (2008) The impact of microRNAs on protein output. Nature 455: 64-71.
6. Barber GN (2011) Cytoplasmic DNA innate immune pathways. Immunol Rev 243: 99-108.
7. Bernardo BC, Charchar FJ, Lin RC, McMullen JR (2012) A microRNA guide for clinicians and basic scientists: background and experimental techniques. Heart Lung Circ 21: 131-142.
8. Bhattacharyya SN, Habermacher R, Martine U, Closs EI, Filipowicz W (2006) Relief of microRNA-mediated translational repression in human cells subjected to stress. Cell 125: 1111-1124.
9. Boudreau RL, Martins I, Davidson BL (2009) Artificial microRNAs as siRNA shuttles: improved safety as compared to shRNAs in vitro and in vivo. Mol Ther 17: 169-175.
10. Bravo V, Rosero S, Ricordi C, Pastori RL (2007) Instability of miRNA and cDNAs derivatives in RNApreparations. Biochem Biophys Res Commun 353: 1052-1055.
11. Chen Y, Zhu X, Zhang X, Liu B, Huang L (2010) Nanoparticles modified with tumor-targeting scFv deliver siRNA and miRNA for cancer therapy. Mol Ther 18: 1650-1656.
12. Chistiakov DA, Sobenin IA, Orekhov AN (2012) Strategies to deliver microRNAs as potential therapeutics in the treatment of cardiovascular pathology. Drug Deliv 19: 392-405.
13. Cui EH, Li HJ, Hua F, Wang B, Mao W, Feng XR, Li JY, Wang X (2013) Serum microRNA 125b as a diagnostic or prognostic biomarker for advanced NSCLC patients receiving cisplatin-based chemotherapy. Acta Pharmacol Sin 34: 309-313.
14. De Guire V, Caron M, Scott N, Menard C, Gaumont-Leclerc MF, Chartrand P, Major F, Ferbeyre G (2010) Designing small multiple-target artificial RNAs. Nucleic Acids Res 38: e140.
15. De Paula D, BentleyMV, Mahato RI (2007) Hydrophobization and bioconjugation for enhanced siRNA delivery and targeting. RNA 13: 431-456.
16. De Rosa G, De Stefano D, Galeone A (2010) Oligonucleotide delivery in cancer therapy. Expert Opin Drug Deliv 7: 1263-1278.
17. Elmen J, Lindow M, Schutz S, Lawrence M, Petri A, Obad S, Lindholm M, Hedtjarn M, Hansen HF, Berger U, Gullans S, Kearney P, Sarnow P, Straarup EM, Kauppinen S (2008) LNA-mediated microRNA silencing in non-human primates. Nature 452: 896-899.
18. Fiedler J, Jazbutyte V, Kirchmaier BC, Gupta SK, Lorenzen J, Hartmann D, Galuppo P, Kneitz S, Pena JT, Sohn-Lee C, Loyer X, Soutschek J, Brand T, Tuschl T, Heineke J, Martin U, Schulte-Merker S, Ertl G, Engelhardt S, Bauersachs J, Thum T (2011) MicroRNA-24 regulates vascularity after myocardial infarction. Circulation 124: 720-730.
19. Friedman RC, Farh KK, Burge CB, Bartel DP (2009) Most mammalian mRNAs are conserved targets of microRNAs. Genome Res 19: 92-105.
20. Garzon R, Heaphy CE, Havelange V, Fabbri M, Volinia S, Tsao T, Zanesi N, Kornblau SM, Marcucci G, Calin GA, Andreeff M, Croce CM (2009) MicroRNA 29b functions in acute myeloid leukemia. Blood 114: 5331-5341.
21. Garzon R, Marcucci G, Croce CM (2010) Targeting microRNAs in cancer: rationale, strategies and challenges. Nat Rev Drug Discov 9: 775-789.
22. Grimm D, Streetz KL, Jopling CL, Storm TA, Pandey K, Davis CR, Marion P, Salazar F, Kay MA (2006) Fatality in mice due to oversaturation of cellular microRNA/short hairpin RNA pathways. Nature 441: 537-541.
23. Grueter CE, van Rooij E, Johnson BA, DeLeon SM, Sutherland LB, Qi X, Gautron L, Elmquist JK, Bassel-Duby R, Olson EN (2012) A cardiac microRNA governs systemic energy homeostasis by regulation of MED13. Cell 149: 671-683.
24. Guo L, Zhao RC,Wu Y (2011) The role of microRNAs in self-renewal and differentiation of mesenchymal stem cells. Exp Hematol 39: 608-616.
25. Hacein-Bey-Abina S, Von Kalle C, Schmidt M, McCormack MP,Wulffraat N, Leboulch P, Lim A, Osborne CS, Pawliuk R, Morillon E, Sorensen R, Forster A, Fraser P, Cohen JI, de Saint Basile G, Alexander I,Wintergerst U, Frebourg T, Aurias A, Stoppa-Lyonnet D, Romana S, Radford-Weiss I, Gross F, Valensi F, Delabesse E, Macintyre E, Sigaux F, Soulier J, Leiva LE, Wissler M, Prinz C, Rabbitts TH, Le Deist F, Fischer A, Cavazzana-Calvo M (2003) LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. Science 302: 415-419.
26. Haraguchi T, Ozaki Y, Iba H (2009) Vectors expressing efficient RNA decoys achieve the long-term suppression of specific microRNA activity in mammalian cells. Nucleic Acids Res 37: e43.
27. Henrion-Caude A, Girard M, Amiel J (2012) MicroRNAs in genetic disease: rethinking the dosage. Curr Gene Ther 12: 292-300.
28. Henry SP, Beattie G, Yeh G, Chappel A, Giclas P, Mortari A, Jagels MA, Kornbrust DJ, Levin AA (2002) Complement activation is responsible for acute toxicities in rhesus monkeys treated with a phosphorothioate oligodeoxynucleotide. Int Immunopharmacol 2: 1657-1666.
29. Hong S, Kim KY,Wook HJ, Park SY, Lee KD, Lee DY, Lee H (2011) Attenuation of the in vivo toxicity of biomaterials by polydopamine surface modification. Nanomedicine (Lond) 6: 793-801.
30. Hughes AE, Bradley DT, Campbell M, Lechner J, Dash DP, Simpson DA, Willoughby CE (2011) Mutation altering the miR-184 seed region causes familial keratoconus with cataract. Am J Hum Genet 89: 628-633.
31. Iwai N, Naraba H (2005) Polymorphisms in human pre-miRNAs. Biochem Biophys Res Commun 331: 1439-1444.
32. Jackson AL, Bartz SR, Schelter J, Kobayashi SV, Burchard J, Mao M, Li B, Cavet G, Linsley PS (2003) Expression profiling reveals off-target gene regulation by RNAi. Nat Biotechnol 21: 635-637.
33. Jackson AL, Burchard J, Schelter J, Chau BN, Cleary M, Lim L, Linsley PS (2006) Widespread siRNA "off-target" transcript silencing mediated by seed region sequence complementarity. RNA 12: 1179-1187.
34. Jopling CL, Yi M, Lancaster AM, Lemon SM, Sarnow P (2005) Modulation of hepatitis C virus RNA abundance by a liver-specific MicroRNA. Science 309: 1577-1581.
35. Judge A, MacLachlan I (2008) Overcoming the innate immune response to small interfering RNA. Hum Gene Ther 19: 111-124.
36. Karlsen TA, Brinchmann JE (2013) Liposome delivery of microRNA-145 to mesenchymal stem cells leads to immunological off-target effects mediated by RIG-I. Mol Ther 21: 1169-1181.
37. Khatri N, Rathi M, Baradia D, Trehan S, Misra A (2012) In vivo delivery aspects of miRNA, shRNA and siRNA. Crit Rev Ther Drug Carrier Syst 29: 487-527.
38. Klinghoffer RA, Magnus J, Schelter J, Mehaffey M, Coleman C, Cleary MA(2010) Reduced seed region-based off-target activity with lentivirusmediated RNAi. RNA 16: 879-884.
39. Kong KY, Owens KS, Rogers JH, Mullenix J, Velu CS, Grimes HL, Dahl R (2010) MIR-23A microRNA cluster inhibits B-cell development. Exp Hematol 38: 629-640 e1.
40. Krutzfeldt J, Rajewsky N, Braich R, Rajeev KG, Tuschl T, Manoharan M, Stoffel M (2005) Silencing of microRNAs in vivo with 'antagomirs'. Nature 438: 685-689.
41. Landi D, Gemignani F, Naccarati A, Pardini B, Vodicka P, Vodickova L, Novotny J, Forsti A, Hemminki K, Canzian F, Landi S (2008) Polymorphisms within micro-RNA-binding sites and risk of sporadic colorectal cancer. Carcinogenesis 29: 579-584.
42. Lanford RE, Hildebrandt-Eriksen ES, Petri A, Persson R, LindowM, Munk ME, Kauppinen S, Orum H (2010) Therapeutic silencing of microRNA-122 in primates with chronic hepatitis C virus infection. Science 327: 198-201.
43. Laterza OF, Lim L, Garrett-Engele PW, Vlasakova K, Muniappa N, Tanaka WK, Johnson JM, Sina JF, Fare TL, Sistare FD, GlaabWE(2009) Plasma MicroRNAs as sensitive and specific biomarkers of tissue injury. Clin Chem 55: 1977-1983.
44. Lee RC, Feinbaum RL, AmbrosV(1993) The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell 75: 843-854.
45. Li QJ, Chau J, Ebert PJ, Sylvester G, Min H, Liu G, Braich R, Manoharan M, Soutschek J, Skare P, Klein LO, Davis MM, Chen CZ (2007) miR-181a is an intrinsic modulator of T cell sensitivity and selection. Cell 129: 147-161.
46. Li Z, Hassan MQ, Jafferji M, Aqeilan RI, Garzon R, Croce CM, vanWijnen AJ, Stein JL, Stein GS, Lian JB (2009) Biological functions of miR-29b contribute to positive regulation of osteoblast differentiation. J Biol Chem 284: 15676-15684.
47. Lim LP, Lau NC, Garrett-Engele P, Grimson A, Schelter JM, Castle J, Bartel DP, Linsley PS, Johnson JM (2005) Microarray analysis shows that some microRNAs downregulate large numbers of target mRNAs. Nature 433: 769-773.
48. Liu X, Yu J, Jiang L, Wang A, Shi F, Ye H, Zhou X (2009) MicroRNA-222 regulates cell invasion by targeting matrix metalloproteinase 1 (MMP1) and manganese superoxide dismutase 2 (SOD2) in tongue squamous cell carcinoma cell lines. Cancer Genomics Proteomics 6: 131-139.
49. Love TM, Moffett HF, Novina CD (2008) Not miR-ly small RNAs: big potential for microRNAs in therapy. J Allergy Clin Immunol 121: 309-319.
50. Lu C, Huang X, Zhang X, Roensch K, Cao Q, Nakayama KI, Blazar BR, Zeng Y, Zhou X (2011) miR-221 and miR-155 regulate human dendritic cell development, apoptosis, and IL-12 production through targeting of p27kip1, KPC1, and SOCS-1. Blood 117: 4293-4303.
51. Lu LF, BoldinMP, Chaudhry A, Lin LL, Taganov KD, Hanada T,Yoshimura A, Baltimore D, Rudensky AY (2010) Function of miR-146a in controlling Treg cell-mediated regulation of Th1 responses. Cell 142: 914-929.
52. Ma L, Reinhardt F, Pan E, Soutschek J, Bhat B, Marcusson EG, Teruya-Feldstein J, BellGW,Weinberg RA (2010) Therapeutic silencing of miR-10b inhibits metastasis in a mousemammarytumor model. Nat Biotechnol 28: 341-347.
53. Mraz M, Malinova K, Mayer J, Pospisilova S (2009) MicroRNA isolation and stability in stored RNA samples. Biochem Biophys Res Commun 390: 1-4.
54. Nan Y, Han L, Zhang A, Wang G, Jia Z, Yang Y, Yue X, Pu P, Zhong Y, Kang C (2010) MiRNA-451 plays a role as tumor suppressor in human glioma cells. Brain Res 1359: 14-21.
55. O'Loughlin AJ,Woffindale CA,Wood MJ (2012) Exosomes and the emerging field of exosome-based gene therapy. Curr Gene Ther 12: 262-274.
56. Olejniczak M, Galka-Marciniak P, Polak K, Fligier A, KrzyzosiakWJ(2012) RNAimmuno: a database of the nonspecific immunological effects of RNA interference and microRNA reagents. RNA 18: 930-935.
57. Pereira DM, Rodrigues PM, Borralho PM, Rodrigues CM (2013) Delivering the promise of miRNA cancer therapeutics. Drug Discov Today 18: 282-289.
58. Purow B (2011) The elephant in the room: do microRNA-based therapies have a realistic chance of succeeding for brain tumors such as glioblastoma? J Neurooncol 103: 429-436.
59. Qi J, Mu D (2012) MicroRNAs and lung cancers: from pathogenesis to clinical implications. Front Med 6: 134-155.
60. Ranganathan P, Heaphy CE, Costinean S, Stauffer N, Na C, Hamadani M, Santhanam R, Mao C, Taylor PA, Sandhu S, He G, Shana'ah A, Nuovo GJ, Lagana A, Cascione L, Obad S, Broom O, Kauppinen S, Byrd JC, Caligiuri M, Perrotti D, Hadley GA, Marcucci G, Devine SM, Blazar BR, Croce CM, Garzon R (2012) Regulation of acute graft-versus-host disease by microRNA-155. Blood 119: 4786-4797.
61. Sarma NJ, Tiriveedhi V, Ramachandran S, Crippin J, Chapman W, Mohanakumar T (2012) Modulation of immune responses following solid organ transplantation by microRNA. Exp Mol Pathol 93: 378-385.
62. Saunders MA, Liang H, Li WH (2007) Human polymorphism at microRNAs and microRNA target sites. Proc Natl Acad Sci U S A 104: 3300-3305.
63. Schwarz DS, Hutvagner G, Du T, Xu Z, Aronin N, Zamore PD (2003) Asymmetry in the assembly of the RNAi enzyme complex. Cell 115: 199-208.
64. Selbach M, Schwanhausser B, Thierfelder N, Fang Z, Khanin R, RajewskyN (2008)Widespread changes in protein synthesis induced by microRNAs. Nature 455: 58-63.
65. Sethupathy P, Collins FS (2008) MicroRNA target site polymorphisms and human disease. Trends Genet 24: 489-497.
66. Seto AG (2010) The road toward microRNA therapeutics. Int J Biochem Cell Biol 42: 1298-1305.
67. Sheehan JP, Phan TM (2001) Phosphorothioate oligonucleotides inhibit the intrinsic tenase complex by an allosteric mechanism. Biochemistry 40: 4980-4989.
68. Shi B, Sepp-Lorenzino L, Prisco M, Linsley P, deAngelis T, Baserga R (2007) MicroRNA145 targets the insulin receptor substrate-1 and inhibits the growth of colon cancer cells. J Biol Chem 282: 32582-32590.
69. Singh S, Narang AS, Mahato RI (2011) Subcellular fate and off-target effects of siRNA, shRNA, and miRNA. Pharm Res 28: 2996-3015.
70. Singha K, Namgung R, Kim WJ (2011) Polymers in small-interfering RNA delivery. Nucleic Acid Ther 21: 133-147.
71. Smith KM, Guerau-de-Arellano M, Costinean S, Williams JL, Bottoni A, Mavrikis Cox G, Satoskar AR, Croce CM, Racke MK, Lovett-Racke AE, Whitacre CC (2012) miR-29ab1 deficiency identifies a negative feedback loop controlling Th1 bias that is dysregulated in multiple sclerosis. J Immunol 189: 1567-1576.
72. Solda G, Robusto M, Primignani P, Castorina P, Benzoni E, Cesarani A, Ambrosetti U, Asselta R, Duga S (2012) A novel mutation within the MIR96 gene causes non-syndromic inherited hearing loss in an Italian family by altering pre-miRNA processing. Hum Mol Genet 21: 577-585.
73. Song E, Lee SK, Wang J, Ince N, Ouyang N, Min J, Chen J, Shankar P, Lieberman J (2003) RNA interference targeting Fas protects mice from fulminant hepatitis. Nat Med 9: 347-351.
74. Spiegel JC, Lorenzen JM, Thum T (2011) Role of microRNAs in immunity and organ transplantation. Expert Rev Mol Med 13: e37.
75. Takagi S, Nakajima M, Kida K, Yamaura Y, Fukami T, Yokoi T (2010) MicroRNAs regulate human hepatocyte nuclear factor 4alpha, modulating the expression of metabolic enzymes and cell cycle. J Biol Chem 285: 4415-4422.
76. Tasaka S, Kamata H, Miyamoto K, Nakano Y, Shinoda H, Kimizuka Y, Fujiwara H, Hasegawa N, Fujishima S, Miyasho T, Ishizaka A (2009) Intratracheal synthetic CpG oligodeoxynucleotide causes acute lung injury with systemic inflammatory response. Respir Res 10: 84.
77. Tserel L, Runnel T, Kisand K, Pihlap M, Bakhoff L, Kolde R, Peterson H, Vilo J, Peterson P, Rebane A (2011) MicroRNA expression profiles of human blood monocyte-derived dendritic cells and macrophages reveal miR-511 as putative positive regulator of Toll-like receptor 4. J Biol Chem 286: 26487-26495.
78. Tsuchiya Y, Nakajima M, Takagi S, Taniya T, Yokoi T (2006) MicroRNA regulates the expression of human cytochrome P450 1B1. Cancer Res 66: 9090-9098.
79. Valastyan S, Benaich N, Chang A, Reinhardt F, Weinberg RA (2009) Concomitant suppression of three target genes can explain the impact of a microRNA on metastasis. Genes Dev 23: 2592-2597.
80. van Rooij E, Purcell AL, Levin AA (2012) Developing microRNA therapeutics. Circ Res 110: 496-507.
81. van Rooij E, Quiat D, Johnson BA, Sutherland LB, Qi X, Richardson JA, Kelm RJ, Jr., Olson EN (2009) A family of microRNAs encoded by myosin genes governs myosin expression and muscle performance. Dev Cell 17: 662-673.
82. Wang J, Lu Z,Wientjes MG, Au JL (2010) Delivery of siRNA therapeutics: barriers and carriers. AAPS J 12: 492-503.
83. Wang QZ, Lv YH, Gong YH, Li ZF, Xu W, Diao Y, Xu R (2012) Doublestranded Let-7 mimics, potential candidates for cancer gene therapy. J Physiol Biochem 68: 107-119.
84. Wang Y, Zhang X, Li H, Yu J, Ren X (2013) The role of miRNA-29 family in cancer. Eur J Cell Biol 92: 123-128.
85. Warnock JN, Daigre C, Al-Rubeai M (2011) Introduction to viral vectors. Methods Mol Biol 737: 1-25.
86. Wightman B, Ha I, Ruvkun G (1993) Posttranscriptional regulation of the heterochronic gene lin-14 by lin-4 mediates temporal pattern formation in C. elegans. Cell 75: 855-862.
87. Wu W (2011) MicroRNAs patents: the road from bench to bedsides for cancer treatment. Recent Pat DNA Gene Seq 5: 86-91.
88. Xiao C, Srinivasan L, Calado DP, Patterson HC, Zhang B,Wang J, Henderson JM, Kutok JL, Rajewsky K (2008) Lymphoproliferative disease and autoimmunity in mice with increased miR-17-92 expression in lymphocytes. Nat Immunol 9: 405-414.
89. Xu Y, Fang F, Zhang J, Josson S, St Clair WH, St Clair DK (2010) miR-17∗suppresses tumorigenicity of prostate cancer by inhibiting mitochondrial antioxidant enzymes. PLoS One 5: e14356.
90. Yeung ML, Jeang KT (2011) MicroRNAs and cancer therapeutics. Pharm Res 28: 3043-3049.
91. Yokoi T, Nakajima M (2011) Toxicological implications of modulation of gene expression by microRNAs. Toxicol Sci 123: 1-14.
92. Yokoi T, Nakajima M (2013) microRNAs as mediators of drug toxicity. Annu Rev Pharmacol Toxicol 53: 377-400.
93. Zhou B, Wang S, Mayr C, Bartel DP, Lodish HF (2007) miR-150, a microRNA expressed in mature B and T cells, blocks early B cell development when expressed prematurely. Proc Natl Acad Sci U S A 104: 7080-7085.